CYTK vs DNLI: fair value comparison
Cytokinetics, Incorporated and Denali Therapeutics Inc. · Updated 2026-10-19
CYTK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DNLI has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CYTK currently ranks higher by quality score.
| CYTK | DNLI | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $61.95 | $17.61 |
| 12-month range | $57.50–$87.26 | $14.41–$27.21 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #98 of 301 Healthcare | #99 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: CYTK fair value analysis · DNLI fair value analysis